Search

Xencor Inc

Закрыт

СекторЗдравоохранение

23.21 1.49

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

22.48

Макс.

23.41

Ключевые показатели

By Trading Economics

Доход

-22M

-151M

Продажи

47M

51M

Прибыль на акцию

-0.29

Рентабельность продаж

-294.108

Сотрудники

260

EBITDA

109M

-12M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+31.75% upside

Дивиденды

By Acuity

Следующий отчет о доходах

3 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

166M

1.6B

Предыдущая цена открытия

21.72

Предыдущая цена закрытия

23.21

Xencor Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

14 авг. 2026 г., 19:16 UTC

Shares of Xencor Inc. are modestly higher amid cautious broader market sentiment following a decline in U.S. retail sales for July.

13 авг. 2026 г., 19:21 UTC

Xencor Inc shares are lower today, with no specific news driving the decline. High trading volume suggests increased activity amid routine fluctuations.

12 авг. 2026 г., 19:56 UTC

Social Media

Xencor Inc shares are higher, supported by social media discussions valuing the company at $1.3 billion based on its ENPP3 asset potential.

11 авг. 2026 г., 19:26 UTC

Xencor Inc shares are advancing, continuing a four-session trend. Investors are focused on upcoming inflation reports that may influence market sentiment.

10 авг. 2026 г., 19:31 UTC

News

Xencor Inc shares are higher today, buoyed by increased institutional investments from Dimensional Fund Advisors and BVF Inc. IL.

7 авг. 2026 г., 23:16 UTC

Xencor Inc shares are higher in after-market trading, supported by decreased interest rate hike expectations following a Labor Department report on non-farm payrolls.

6 авг. 2026 г., 20:03 UTC

News

Xencor shares are higher as Cantor Fitzgerald raises its price target to $44, reflecting confidence in the company's pipeline and upcoming ESMO Congress presentation.

3 авг. 2026 г., 19:51 UTC

Xencor Inc's shares are declining, continuing a downward trend since Friday's close, despite a broader market rally in technology and airlines.

31 июл. 2026 г., 20:03 UTC

Xencor Inc shares are lower, reversing earlier gains amid rising US Treasury yields and crude oil prices, contributing to inflation concerns and interest rate expectations.

30 июл. 2026 г., 19:03 UTC

News
Social Media

Xencor Inc. gains following a $105 million settlement with Alexion, boosting investor confidence and extending its operating runway through 2028.

29 июл. 2026 г., 19:36 UTC

Xencor Inc. shares are lower as broader market trends decline ahead of the Federal Reserve's policy announcement, amid rising oil prices and inflation concerns.

28 июл. 2026 г., 20:07 UTC

Xencor Inc is gaining amid a strong Biotechnology sector, despite earlier declines. The stock has rebounded to settle near the upper end of its one-month range.

27 июл. 2026 г., 19:11 UTC

Xencor Inc shares are higher today, reflecting a positive market environment despite earlier intraday pullbacks. No specific news was identified to explain the movement.

24 июл. 2026 г., 19:11 UTC

Xencor Inc shares are lower in Friday's session, reflecting broader market trends. No specific news was identified to explain the price movement.

22 июл. 2026 г., 20:06 UTC

Xencor Inc shares are lower today, retracing from an earlier peak. Broader market sentiment is affected by uncertainty ahead of the Federal Reserve meeting.

21 июл. 2026 г., 19:02 UTC

Social Media

Xencor Inc. shares reached a new 52-week high, driven by developments in RCC related to ENPP3 and immuno-oncology efforts involving TL1A.

20 июл. 2026 г., 19:41 UTC

Social Media

Xencor Inc's shares are higher as clinical results are accepted for presentation at the ESMO conference, with a Phase 3 trial planned for 2027.

Сравнение c конкурентами

Изменение цены

Xencor Inc Прогноз

Целевая цена

By TipRanks

31.75% рост

Прогноз на 12 месяцев

Средняя 30.29 USD  31.75%

Максимум 44 USD

Минимум 20 USD

Основано на мнении 10 аналитиков Wall Street, спрогнозировавших целевые цены для Xencor Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

10 ratings

9

Покупка

1

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.
help-icon Live chat